Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 6/20 | 0.46 |
| ▸ | PRKCA | P17252 | 1/20 | 0.45 |
| ▸ | MMP12 | P39900 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 13/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 13/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12894489 | 0.89 | SCN9A (0.50) | SCN9ACYP3A4CYP2C19CYP2C9CYP2D6 | |
| SCHEMBL2902525 | 0.83 | PRKCA (0.44) | SCN9APRKCAMMP12CYP3A4CYP2C19 | |
| SCHEMBL4431910 | 0.78 | CYP3A4 (0.58) | SCN9APRKCAMMP12CYP3A4CYP2C19 | |
| SCHEMBL5517804 | 0.78 | HTR2A (0.52) | SCN9APRKCAMMP12CYP3A4CYP2C19 | |
| SCHEMBL903153 | 0.78 | SCN9A (0.48) | SCN9APRKCAMMP12CYP3A4CYP2C19 | |
| SCHEMBL904335 | 0.78 | SCN9A (0.48) | SCN9APRKCAMMP12CYP3A4CYP2C19 | |
| SCHEMBL2998597 | 0.78 | AAK1 (0.33) | SCN9A | |
| SCHEMBL6388916 | 0.77 | SCN9A (0.72) | SCN9APRKCAMMP12CYP3A4CYP2C19 | |
| SCHEMBL14452260 | 0.77 | CYP3A4 (0.59) | SCN9APRKCAMMP12CYP3A4CYP2C19 | |
| SCHEMBL1261240 | 0.76 | CYP3A4 (0.62) | SCN9APRKCAMMP12CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120020920-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-20120020920-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-2335700-A1 | Hepatitis C virus polymerase inhibitors with a heterobicylic structure | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2011-06-22 | — | — | EP | disclosed |
| EP-2335700-A1 | Hepatitis C virus polymerase inhibitors with a heterobicylic structure | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2011-06-22 | — | — | EP | disclosed |
| US-7893084-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM CANADA LTD. (CA) | 2011-02-22 | — | — | US | disclosed |
| US-7893084-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM CANADA LTD. (CA) | 2011-02-22 | — | — | US | disclosed |
| US-7157486-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2007-01-02 | — | — | US | disclosed |
| US-7157486-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2007-01-02 | — | — | US | disclosed |
| US-7157486-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2007-01-02 | — | — | US | disclosed |
| US-20060293306-A1 | Viral Polymerase Inhibitors | BEAULIEU PIERRE L | 2006-12-28 | — | — | US | disclosed |
| US-7141574-B2 | Series of fused heterocycle compounds having improved inhibitory activity against HCV polymerase; hepatitis treatment | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2006-11-28 | — | — | US | disclosed |
| US-20060160798-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2006-07-20 | — | — | US | disclosed |
| EP-1414797-A2 | HEPATITIS C VIRUS POLYMERASE INHIBITORS WITH A HETEROBICYLIC STRUCTURE | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-05-06 | — | — | EP | disclosed |
| US-20040024190-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-02-05 | — | — | US | disclosed |
| US-20030176433-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-09-18 | — | — | US | disclosed |
| WO-2003010141-A2 | HEPATITIS C VIRUS POLYMERASE INHIBITORS WITH A HETEROBICYCLIC STRUCTURE | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120020920-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | GTF3C5, ZC3HAV1, POLI | SCN9A 3095/4885PRKCA 2801/4885MMP12 1817/4885 |
| US-20030176433-A1 | Viral polymerase inhibitors | NR4A1, RCOR1, RER1 | SCN9A 1198/4885PRKCA 3908/4885MMP12 3790/4885 |
| US-20060293306-A1 | Viral Polymerase Inhibitors | NR2C2, NR4A1, POLR2A | SCN9A 2500/4885PRKCA 4313/4885MMP12 2226/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | SCN9A 3087/4885PRKCA 2404/4885MMP12 1013/4885 |
| US-20060160798-A1 | Viral polymerase inhibitors | NR4A1, NR1I3, RER1 | SCN9A 1507/4885PRKCA 3480/4885MMP12 3559/4885 |
| US-20040024190-A1 | Viral polymerase inhibitors | RCOR1, NR4A1, RER1 | SCN9A 655/4885PRKCA 3690/4885MMP12 3511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.